Jim P Tol1, Max Dahele2, Vincent Gregoire3, Jens Overgaard4, Ben J Slotman2, Wilko F A R Verbakel5. 1. VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands. Electronic address: j.tol.vumc@gmail.com. 2. VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands. 3. Université catholique de Louvain, St-Luc University Hospital, Experimental and Clinical Research Institute, Center for Molecular Imaging, Oncology and Radiotherapy, Brussels, Belgium. 4. Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark. 5. VU University Medical Center, Department of Radiation Oncology, Amsterdam, The Netherlands. Electronic address: w.verbakel@vumc.nl.
Abstract
INTRODUCTION: Radiotherapy treatment plan quality can influence clinical trial outcomes and general QA may not identify suboptimal organ-at-risk (OAR) sparing. We retrospectively performed patient-specific quality assurance (QA) of 100 head-and-neck cancer (HNC) plans from the EORTC-1219-DAHANCA-29 study. MATERIALS AND METHODS: A 177-patient RapidPlan (Varian Medical Systems) model comprising institutional HNC plans was used to QA trial plans (Ptrial). RapidPlan plans (Prapidplan) were created using RapidPlan and Eclipse scripting to achieve a high degree of automation. Comparison between Prapidplan mean predicted/achieved OAR doses, and Ptrial mean OAR doses was made for parotid/submandibular glands (PGs/SMGs) and swallowing muscles (SM). RESULTS: OAR predictions were made within 2 min per patient. Averaged PG/SMG/SM mean doses were 2.0/9.0/3.8 Gy lower in Prapidplan. Using predicted Prapidplan combined mean OAR dose as the benchmark, a total of 60/27/4 trial plans could be improved by 3/6/9 Gy respectively. DISCUSSION: Individualized QA indicated that OAR sparing could frequently be improved in EORTC-1219 study plans, even though they met the trial's generic plan criteria. Automated, patient-specific QA can be performed within a few minutes and should be considered to reduce the influence of planning variation on trial outcomes.
INTRODUCTION: Radiotherapy treatment plan quality can influence clinical trial outcomes and general QA may not identify suboptimal organ-at-risk (OAR) sparing. We retrospectively performed patient-specific quality assurance (QA) of 100 head-and-neck cancer (HNC) plans from the EORTC-1219-DAHANCA-29 study. MATERIALS AND METHODS: A 177-patient RapidPlan (Varian Medical Systems) model comprising institutional HNC plans was used to QA trial plans (Ptrial). RapidPlan plans (Prapidplan) were created using RapidPlan and Eclipse scripting to achieve a high degree of automation. Comparison between Prapidplan mean predicted/achieved OAR doses, and Ptrial mean OAR doses was made for parotid/submandibular glands (PGs/SMGs) and swallowing muscles (SM). RESULTS: OAR predictions were made within 2 min per patient. Averaged PG/SMG/SM mean doses were 2.0/9.0/3.8 Gy lower in Prapidplan. Using predicted Prapidplan combined mean OAR dose as the benchmark, a total of 60/27/4 trial plans could be improved by 3/6/9 Gy respectively. DISCUSSION: Individualized QA indicated that OAR sparing could frequently be improved in EORTC-1219 study plans, even though they met the trial's generic plan criteria. Automated, patient-specific QA can be performed within a few minutes and should be considered to reduce the influence of planning variation on trial outcomes.
Authors: Kirsten van Gysen; Andrew Kneebone; Andrew Le; Kenny Wu; Annette Haworth; Regina Bromley; George Hruby; James O'Toole; Jeremy Booth; Chris Brown; Maria Pearse; Mark Sidhom; Kirsty Wiltshire; Colin Tang; Thomas Eade Journal: Phys Imaging Radiat Oncol Date: 2022-05-13
Authors: Roni Hytönen; Marije R Vergeer; Reynald Vanderstraeten; Timo K Koponen; Christel Smith; Wilko F A R Verbakel Journal: Adv Radiat Oncol Date: 2022-01-28
Authors: Ane L Appelt; Ellen M Kerkhof; Lars Nyvang; Ernst C Harderwijk; Natalie L Abbott; Mark Teo; Femke P Peters; Camilla J S Kronborg; Karen-Lise G Spindler; David Sebag-Montefiore; Corrie A M Marijnen Journal: Tech Innov Patient Support Radiat Oncol Date: 2019-10-15
Authors: Nicholas Hardcastle; Olivia Cook; Xenia Ray; Alisha Moore; Kevin L Moore; David Pryor; Alana Rossi; Farshad Foroudi; Tomas Kron; Shankar Siva Journal: Radiat Oncol Date: 2021-08-03 Impact factor: 3.481